ストックスクリーナーアプリを入手
2.07
2.36%
-0.05
アフターアワーズ：
2.17
0.10
+4.83%
前日終値:
$2.12
開ける：
$2.1
24時間の取引高:
166.16K
Relative Volume:
0.62
時価総額：
$112.80M
収益：
-
当期純損益:
$-121.83M
株価収益率:
-0.9539
EPS:
-2.17
ネットキャッシュフロー:
$-110.58M
1週間 パフォーマンス:
-12.66%
1か月 パフォーマンス:
-60.19%
6か月 パフォーマンス:
-56.33%
1年 パフォーマンス:
-33.01%
1日の値動き範囲:
$2.00
$2.16
1週間の範囲:
$1.98
$2.448
52週間の値動き範囲:
$1.66
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World
First Trust NASDAQ ABA Community Bank Index Fund (NASDAQ:QABA) Short Interest Update - Defense World
RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World
Nordstrom, Inc. (NYSE:JWN) Shares Sold by Axa S.A. - Defense World
Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo
Firstsource Acquires Ascensos - MENAFN.COM
Firstsource acquires UK-based Ascensos for $56 million - The Economic Times
Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting
19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute
First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo
Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online
Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo
Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News
Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World
A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle
Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St
Ratios Reveal: Breaking Down Prelude Therapeutics Inc (PRLD)’s Financial Health - The Dwinnex
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MyChesCo
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Receives Neutral Rating from HC Wainwright - Defense World
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 - MyChesCo
Prelude Therapeutics' (PRLD) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3% - MarketBeat
Prelude reports safety of new cancer drug at ESMO Congress By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - Yahoo Finance
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development - MyChesCo
Glioblastoma Pipeline Drugs, Treatment Therapies, Clinical Trials, and Companies 2024 - openPR
A Look at Prelude Therapeutics Inc (PRLD) Shares in the Recent Past Indicates Growth - SETE News
Financial Metrics Check: Prelude Therapeutics Inc (PRLD)’s Ratios for Trailing Twelve Months - The Dwinnex
Prelude Therapeutics Inc (PRLD) did well last session? - US Post News
MSD discontinues two Phase III Keytruda trials - Clinical Trials Arena
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates - MyChesCo
Glioblastoma Pipeline Drugs 2024 | Denovo BioPharma, Pfizer, - openPR
The Globe and Mail - The Globe and Mail
HC Wainwright Equities Analysts Lower Earnings Estimates for Prelude Therapeutics Incorporated (NASDAQ:PRLD) - MarketBeat
Vanguard Group Inc. Raises Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Vanguard Group Inc. Buys 10,143 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
HC Wainwright Weighs in on Prelude Therapeutics Incorporated’s Q1 2025 Earnings (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) Rating Reiterated by HC Wainwright - Defense World
Prelude Therapeutics Incorporated Forecasted to Post Q1 2025 Earnings of ($0.49) Per Share (NASDAQ:PRLD) - MarketBeat
HC Wainwright Reaffirms Neutral Rating for Prelude Therapeutics (NASDAQ:PRLD) - MarketBeat
Pathos AI Licenses PRT811 From Prelude Therapeutics - Contract Pharma
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 46.0% in July - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Issues Quarterly Earnings Results, Meets Estimates - MarketBeat
PRLD stock soars to 52-week high, touches $6.8 amid growth - Investing.com India
Financial Review: Prelude Therapeutics (NASDAQ:PRLD) and Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):